Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Eighth International Conference On Bipolar Disorder To Be Held In Pittsburgh, June 25 To 27
Nearly 1,000 researchers, clinicians and mental health advocates are expected to attend the Eighth International Conference on Bipolar Disorder, June 25 to 27, at the David L. Lawrence Convention Center in Pittsburgh. The event is held only once every two years and is the largest meeting of its kind solely devoted to bipolar disorder, a disease that affects almost six million Americans.
generic viagra online
Fenofibrate Reduces Risk Of First Amputation For Type 2 Diabetics By 36%
Using fenofibrate to lower blood fats in people with type 2 diabetes reduces the risk of a first diabetes-related amputation by 36%. This is among the conclusions of the FIELD study, reported in an Article in this week"s diabetes special issue of The Lancet.
News of the day
Chromosomal Problems Affect Nearly All Human Embryos; Discovery May Explain Low Fertility Rates In Humans
For the first time, scientists have shown that chromosomal abnormalities are present in more than 90% of IVF embryos, even those produced by young, fertile couples. Ms Evelyne Vanneste, a PhD student in the Centre for Human Genetics and the University Fertility Center, Leuven University, Belgium, told the 25th annual conference of the European Society of Human Reproduction and Embryology today (Wednesday July 1), that the surprising finding meant that current techniques used in preimplantation genetic screening (PGS), where embryos are screened genetically in order to select the best embryo for transfer, do nothing to improve pregnancy and live birth rates. Indeed, it can lead to potentially viable embryos being discarded, she said.
Nutrition

Another McGill/JGH Breakthrough Opens Door To Early Alzheimer's Diagnosis

A new diagnostic technique which may greatly simplify the detection of Alzheimer"s disease has been discovered by researchers at McGill University and the affiliated Lady Davis Institute for Medical Research at Montreal"s Jewish General Hospital (JGH). Their results were published June 8 in the Journal of Alzheimer"s Disease. There is currently no accepted blood test for Alzheimer"s, and the diagnosis is usually based on expensive and labour-intensive neurological, neuropsychological and neuroimaging evaluations. Dr. Hyman Schipper and colleagues at the Lady Davis Institute and McGill University utilized a new minimally-invasive technique called near-infrared (NIR) biospectroscopy to identify changes in the blood plasma of Alzheimer"s patients, changes which can be detected very early after onset, and possibly in pre-clinical stages of the disease. Biospectroscopy is the medical form of spectroscopy, the science of detecting the composition of substances using light or other forms of energy. In NIR spectroscopy, different substances emit or reflect light at specific, detectable wavelengths. In this study, Schipper and his colleague Dr. David Burns - head of McGill"s Biomedical Laboratory for Informatics, Imaging and Spectroscopy at the department of chemistry - applied near-infrared light to blood plasma samples taken from patients with early Alzheimer"s dementia, mild cognitive impairment (MCI) == an intermediate state between normal cognition and dementia -- and healthy elderly control subjects at the JGH/McGill Memory Clinic. Using this technique, the researchers were able to distinguish Alzheimer"s from healthy controls with 80 per cent sensitivity (correct identification of patients with the disease) and 77 per cent specificity (correct identification of persons without the disease). A significant number of subjects with MCI tested positively with the Alzheimer group, indicating that the test may be capable of detecting Alzheimer disease even before patients" symptoms meet clinical criteria for dementia. "We are very encouraged by these data and look forward to testing this potential diagnostic tool in larger-scale studies", said Schipper, Director of the Centre for Neurotranslational Research at the JGH and professor of neurology and medicine at McGill. Researchers have been searching for a minimally-invasive biological marker that differentiates Alzheimer"s disease from normal aging and other neurodegenerative conditions for decades. "The advent of a simple blood test for the diagnosis of early Alzheimer"s", remarked Schipper, "would represent a major achievement in the management of this common disorder". Notes: Schipper is a noted expert in brain aging and neurodegeneration, and is also medical director (neurosciences) of Molecular Biometrics Inc., a McGill technology-transfer spinoff which licensed the innovative biospectroscopy approach used in this study. In addition to Alzheimer"s disease, Molecular Biometrics is currently developing this diagnostic platform for application in Parkinson"s disease, in vitro fertilization and maternal-fetal health. Mark Shainblum McGill University


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009